
Processa Pharmaceuticals (PCSA) Stock Forecast & Price Target
Processa Pharmaceuticals (PCSA) Analyst Ratings
Bulls say
Processa Pharmaceuticals Inc. has demonstrated a narrowed net loss per share estimate for 2026, decreasing from $0.20 to $0.15, indicating improvements in financial performance while accounting for an increased outstanding share count. The potential for significant value increase is highlighted by upcoming positive interim data from the mid-stage trial of its lead product, NGC-Cap. Additionally, the company has secured a strategic investment and is exploring corporate cryptocurrency treasury strategies, reflecting proactive financial management and growth initiatives.
Bears say
Processa Pharmaceuticals is anticipated to report a full-year net loss of $0.43 per share for 2025, reflecting concerns over regulatory approvals and the potential for increased competition that may hinder pricing and market penetration. The company's current financial performance includes a recent net loss of $0.25 per share, slightly above the projected net loss of $0.23 per share, signaling ongoing financial challenges. Additionally, risks associated with partnerships and the prospect of dilution in the near to medium term further contribute to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Processa Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Processa Pharmaceuticals (PCSA) Analyst Forecast & Price Prediction
Start investing in Processa Pharmaceuticals (PCSA)
Order type
Buy in
Order amount
Est. shares
0 shares